Statement: The Cohort of the primary trial which received D+C and Taxane Na‚àö√òve, produced marginally better results than the other cohort.
Primary_evidence: Outcome Measurement:    Objective Response Rate (ORR)   Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Objective response (OR) = CR + PR.   Time frame: From date of randomization until the date of first documented progression or date of intolerable toxicity, whichever came first, assessed up to 54 months. Results 1:    Arm/Group Title: D+C and Taxane Naive   Arm/Group Description: Doxil, Carboplatin and Taxane naive   Overall Number of Participants Analyzed: 39   Measure Type: Number   Unit of Measure: percentage of participants  30.8        (17.0 to 47.6) Results 2:    Arm/Group Title: D+C and Taxane Pretreated   Arm/Group Description: Doxil, Carboplatin and Taxane pretreated   Overall Number of Participants Analyzed: 42   Measure Type: Number   Unit of Measure: percentage of participants  31.0        (17.6 to 47.1)